YingSight Medical, XinYue Bio, and Senmai Medical Secure New Funding Rounds, Highlighting Independent R&D

Mar 18, 2024 23:39 CST Updated 23:39

NewDEL Biotech

Antitumor New Drug R&D Company

1. InCellaFly Imaging Completes Angel Round Financing, Embarks on "Wireless" Innovation Journey

Recently, Suzhou InnoEndo Medical Technology Co., Ltd. (hereinafter referred to as "InnoEndo"), a manufacturer of intelligent wireless endoscopes, has completed its angel round of financing. The investors include Guoqian Venture Capital, Relay Fund, and Suzhou Medical Device Industry Group. The funds from this round will be used for the research and development of the company's core products, intelligent wireless rigid and flexible endoscopes, capacity expansion, and market development, among others.

InspireMed is committed to the research, production, and sales of high-end medical devices for minimally invasive surgery. It has developed two innovative product series: intelligent wireless rigid endoscopy and flexible endoscopy systems. Additionally, it has independently developed a wireless system solution that provides a complete set of diagnostic and therapeutic solutions with portable mobility advantages, including wireless endoscopes and wireless ultrasound.

InspireSight's intelligent wireless endoscope product reduces the volume of the traditional image processing host to one-twentieth, transforming it into a handheld device free from cable constraints. Through advanced ultra-low latency wireless image transmission technology and ISP tuning technology, the product achieves latency and clarity levels comparable to traditional wired endoscope systems at 4K and 1080P resolutions.

2. NewDEL Biotech Completes Tens of Millions of Yuan in Series A Financing; Independent Core Technology Drives Breakthroughs in Innovative Drug Development

Recently, Shenzhen NewDEL Biotech Co., Ltd. (hereinafter referred to as "NewDEL Biotech") announced the completion of a multi-million RMB A-round financing. This round of investment was made by the existing shareholder, Hecheng Capital. The continued investment is both a recognition of NewDEL Biotech's past performance and an expectation of its future development potential. This financing will be used to accelerate the domestic Phase I clinical trial of the innovative drug ND-003 project in China, the construction of the DEL+X technology platform (including DEL+AI, i.e., SMART DEL, DEL+protac, and DEL+molecular probes), as well as for the preclinical and early clinical development of other projects within the company.

NewDEL Biotech is the first biopharmaceutical company incubated by Guangdong Province's Small Molecule Innovative Drug Innovation Center. It possesses the world's leading DEL live cell screening technology and is continuously building the DEL+X technology platform, including SMART DEL, DEL+protac, and DEL+molecular probes.

3. Focus on Self-Administration Device Development: Edge Capital Leads Multi-Million Yuan Series A Financing for Sinmai Medical

Zhejiang Senmai Hechuang Medical Technology Co., Ltd. (hereinafter referred to as "Senmai Medical") has completed a multi-million yuan Series A round of financing, led by EF Capital. After the completion of the financing, the company will continue to focus on the development of self-administration devices, accelerate the automation of assembly production lines, and provide domestic and international pharmaceutical companies with comprehensive, reliable, and stable overall solutions for drug delivery devices, assisting pharmaceutical companies in expanding into the global market.

Currently, the company has five platform products, with over 50 patents online. The products cover plastic mechanical drug delivery devices, electronic drug delivery devices, NFC blood glucose monitoring devices, and drug tracking management systems. Multiple drug delivery devices have been contracted with pharmaceutical companies both in China and internationally, and the products will be launched in the market within the next few years.

Editor: Mingyao